Holen Sie sich die Stockscreener-App
9.45
0.79%
-0.09
Schlusskurs vom Vortag:
$9.54
Offen:
$9.47
24-Stunden-Volumen:
220.37K
Relative Volume:
0.08
Marktkapitalisierung:
$2.11B
Einnahmen:
$509.86M
Nettoeinkommen (Verlust:
$165.35M
KGV:
13.94
EPS:
0.6779
Netto-Cashflow:
$107.55M
1W Leistung:
-0.47%
1M Leistung:
-4.39%
6M Leistung:
-40.13%
1J Leistung:
-42.25%
1-Tages-Spanne:
$9.38
$9.5056
1-Wochen-Bereich:
$9.345
$9.65
52-Wochen-Spanne:
$7.2101
$20.46
Adma Biologics Inc Stock (ADMA) Company Profile
Firmenname
Adma Biologics Inc
Sektor
Branche
Telefon
(201) 478-5552
Adresse
C/O ADMA BIOLOGICS, INC., RAMSEY
Compare ADMA vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ADMA
Adma Biologics Inc
|
9.44 | 2.14B | 509.86M | 165.35M | 107.55M | 0.6779 |
VRTX
Vertex Pharmaceuticals Inc
|
522.23 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
800.17 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,000.06 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
138.44 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.05 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
Adma Biologics Inc Stock (ADMA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-21 | Eingeleitet | Canaccord Genuity | Buy |
| 2026-03-26 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-07-19 | Fortgesetzt | Raymond James | Strong Buy |
| 2022-10-13 | Eingeleitet | Mizuho | Buy |
| 2021-11-11 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2021-11-09 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2019-06-04 | Eingeleitet | Jefferies | Buy |
| 2019-04-15 | Bestätigt | H.C. Wainwright | Buy |
| 2019-02-07 | Fortgesetzt | H.C. Wainwright | Buy |
| 2017-12-11 | Bestätigt | Maxim Group | Buy |
| 2017-11-14 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2017-01-23 | Hochstufung | Maxim Group | Hold → Buy |
| 2016-08-01 | Herabstufung | Maxim Group | Buy → Hold |
| 2016-07-25 | Bestätigt | Maxim Group | Buy |
| 2015-05-13 | Bestätigt | Maxim Group | Buy |
| 2014-12-08 | Eingeleitet | Oppenheimer | Outperform |
| 2014-12-01 | Bestätigt | Maxim Group | Buy |
Alle ansehen
Adma Biologics Inc Aktie (ADMA) Neueste Nachrichten
ADMA: Adma Biologics Inc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Adma Biologics (ADMA) Is Considered a Good Investment by Brokers: Is That True? - Yahoo Finance
ADMAAdma Biologics Inc Volatility & Greeks - Finviz
ADMA Biologics Inc (ADMA) Stock Analysis: A Biotech With 76% Potential Upside - DirectorsTalk Interviews
Adma Biologics Stock Price Forecast. Should You Buy ADMA? - StockInvest.us
Adma Biologics (ADMA) Down 4.8% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Trading Systems Reacting to (ADMA) Volatility - Stock Traders Daily
ADMA Tumbles On Slashed Outlook As Short-Seller Aftermath Meets Competitive Headwinds - stocktwits.com
ADMA Biologics: Maybe The Bears Are Right (Rating Downgrade) (NASDAQ:ADMA) - Seeking Alpha
ADMA Biologics Inc (ADMA) Stock Analysis: Exploring A Promising 82% Potential Upside - DirectorsTalk Interviews
ADMA BIOLOGICS, INC. (ADMA) SHAREHOLDER INVESTIGATION ALERT: Bernstein Liebhard Investigates Potential Breaches of Fiduciary Duty - TMX Newsfile
Law firm probes ADMA Biologics' leadership for possible breaches of fiduciary duty to shareholders - Pluang
Class action lawsuit filed against ADMA Biologics for misleading investors and undisclosed transactions - Pluang
ADMA Biologics (ADMA) After Strong Q2 Results And Reaffirmed Guidance Is It A Bargain - Sahm
Nomura Small Cap Growth Fund's ADMA Biologics Inc(ADMA) Holding History - GuruFocus
Investigation launched into ADMA Biologics for alleged revenue inflation via channel-stuffing. - Pluang
ADMA Biologics Inc (ADMA) Stock Analysis: Unpacking the 79% Potential Upside for Investors - DirectorsTalk Interviews
ADMA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
ADMA Biologics Inc (NASDAQ:ADMA) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Bank of America Corp DE Raises Holdings in ADMA Biologics Inc $ADMA - MarketBeat
Why ADMA Biologics (ADMA) Is Up 5.6% After Reaffirming 2026 Revenue Guidance And EPS Momentum - Sahm
Behavioral Patterns of ADMA and Institutional Flows - Stock Traders Daily
ADMA|ADMA Biologics Inc|Price:9.540|Chg%:+0.200 - TradingKey
STATE STREET CORP Buys ADMA Biologics Inc (ADMA) -- Shares Look 49% Undervalued on GF Value - GuruFocus
ADMA Biologics Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Can Asceniv Help ADMA Stock Combat IG Market Challenges? - Yahoo Finance
ADMA Biologics Inc (ADMA) Stock Forecasts - Yahoo Finance
ADMA Biologics: The Earnings Reset Still Leaves More Upside (NASDAQ:ADMA) - Seeking Alpha
Royal Bank of Canada Buys 759,984 Shares of ADMA Biologics Inc $ADMA - MarketBeat
Janus Henderson Group PLC Trims Stock Holdings in ADMA Biologics Inc $ADMA - MarketBeat
ADMA DEADLINEFINAL REMINDER: Bronstein, Gewirtz and Grossman, LLC Reminds Stockholders of ADMA Biologics, Inc. to Contact the Firm Today! - ACCESS Newswire
ADMA Biologics, Inc. Deadline: ADMA Investors Have Opportunity to Lead ADMA Biologics, Inc. Securities Fraud Lawsuit Filed by The Rosen Law Firm - PR Newswire
Bronstein, Gewirtz & Grossman LLC Urges ADMA Biologics, - GlobeNewswire
ADMA Investors Have Opportunity to Lead ADMA Biologics, Inc. Securities Fraud Lawsuit with SBS Law - Business Wire
CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds ADMA Biologics Investors of Securities Class Action Lawsuit Deadline on August 10, 2026 - Voice of Alexandria
ADMA Biologics, Inc. Notice of August 10, 2026 Application Deadline for Class Action LawsuitContact Reed Kathrein at Hagens Berman Sobol Shapiro LLP By Application Deadline - PR Newswire
ADMA Biologics Inc (ADMA): Investor Outlook Highlights 71.72% Potential Upside - DirectorsTalk Interviews
Robbins LLP Reminds ADMA Investors of the August 10, 2026 Lead Plaintiff Deadline; Contact the Firm for Information About Recovering Your Losses - PR Newswire
ADMA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
DEADLINE NEXT WEEK: Hagens Berman Advises ADMA Biologics, Inc. Investors to Contact the Firm Before August 10, 2026 - PR Newswire
BTU IMPORTANT DEADLINE: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Peabody Energy Corporation Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – BTU - GlobeNewswire Inc.
ADMA DEADLINE REMINDER: Bronstein, Gewirtz & Grossman LLC Alerts ADMA Biologics, Inc. Investors to Participate in the Class Action Lawsuit Today - ACCESS Newswire
ADMA Biologics 48 Hour Deadline Alert: Kahn Swick & Foti, LLC Rem - The National Law Review
ADMA SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds ADMA Biolog - The National Law Review
ADMA Biologics 48 Hour Deadline Alert: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuit Against ADMA Biologics, Inc.ADMA - ACCESS Newswire
ADMA SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds ADMA Biologics Investors of Securities Class Action Lawsuit Deadline on August 10, 2026 - accessnewswire.com
ADMA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that ADMA Biologics, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
ADMA Biologics 72 Hour Deadline Alert: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuit Against ADMA Biologics, Inc.ADMA - businesswire.com
ADMA UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds ADMA Biologi - The National Law Review
ADMA 3-DAY DEADLINE ALERT: ADMA Biologics, Inc. Investors - GlobeNewswire
ADMA BIOLOGICS CLASS ACTION DEADLINE AUGUST 10th: Bragar - GlobeNewswire
Finanzdaten der Adma Biologics Inc-Aktie (ADMA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.72%
1.02%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):